Brazil will pilot Ozempic-style weight-loss drugs in its public health system, a demand signal for Novo Nordisk and Eli Lilly once prices fall.

Brazil will pilot Ozempic-style weight-loss drugs in its public health system, a demand signal for Novo Nordisk and Eli Lilly once prices fall.

A Brazilian drugmaker filed to launch its own version of the blockbuster weight-loss and diabetes drug, taking aim at a market worth billions a year.